심혈관 바이오마커 패널 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Cardiovascular Biomarker Panels Market is forecast to grow at a CAGR of 10.5%, reaching USD 18.28 billion in 2031 from USD 7.45 billion in 2026.

The global cardiovascular biomarker panels market is experiencing robust growth, driven by the rising prevalence of cardiovascular diseases and the shift toward comprehensive, multiplex diagnostic strategies. This market encompasses diagnostic assays, laboratory analyzers, reagents, software platforms, and point-of-care testing systems designed to measure multiple biomarkers associated with myocardial injury, cardiac stress, inflammation, and cardiovascular risk. Multiplex biomarker panels enable simultaneous evaluation of complementary biological indicators that collectively improve disease characterization compared with individual biomarker testing. Demand is increasing because cardiovascular disease prevalence, aging populations, and associated risk factors are expanding the number of patients requiring rapid and accurate cardiac evaluation. Traditional single-marker testing frequently provides incomplete clinical information, increasing dependence on multimarker diagnostic strategies that improve sensitivity and prognostic accuracy. Regulatory authorities and professional cardiovascular organizations continue supporting standardized utilization of high-sensitivity cardiac biomarkers within clinical practice guidelines because early diagnosis significantly improves patient outcomes. These structural changes position cardiovascular biomarker panels as an essential component of modern precision cardiovascular medicine.

Market Drivers

Rising Global Burden of Cardiovascular Diseases

• Cardiovascular diseases remain the leading cause of mortality worldwide because aging populations and increasing prevalence of hypertension, diabetes, obesity, and dyslipidemia continue expanding the at-risk patient population. Demand is increasing for comprehensive biomarker panels as clinicians require more accurate tools for diagnosing complex cardiovascular conditions at earlier stages. Conventional laboratory testing frequently provides limited diagnostic information during acute cardiovascular events, creating greater dependence on multiplex biomarker strategies. Healthcare providers are expanding routine cardiovascular biomarker testing to improve clinical outcomes and optimize treatment pathways. This structural transition supports sustained demand for advanced cardiovascular biomarker panels.

Increasing Clinical Adoption of High-Sensitivity Cardiac Biomarkers

• High-sensitivity cardiac biomarkers have become fundamental components of cardiovascular diagnostics because they enable earlier detection of myocardial injury and improve diagnostic accuracy. Hospitals and emergency departments are implementing high-sensitivity cardiac troponin assays alongside natriuretic peptide testing to strengthen evaluation of acute coronary syndrome and heart failure. Laboratory manufacturers are enhancing assay sensitivity and automation to accommodate growing testing volumes while improving analytical precision. Broader clinical adoption strengthens demand for integrated cardiovascular biomarker panels across acute and chronic care settings.

Expansion of Multiplex Diagnostic Technologies

• Multiplex diagnostic platforms improve laboratory efficiency by simultaneously measuring multiple cardiovascular biomarkers from a single patient sample. Healthcare organizations are adopting multiplex assays because consolidated testing reduces turnaround time while providing more comprehensive clinical information. Manufacturers continue expanding biomarker panel portfolios to address evolving clinical requirements and guideline recommendations. These technological developments reinforce demand for integrated diagnostic solutions that support precision cardiovascular medicine.

Growth of Point-of-Care Cardiovascular Diagnostics

• Point-of-care testing enables rapid cardiovascular assessment in emergency departments, ambulances, outpatient clinics, and decentralized healthcare settings where timely diagnosis is critical. Healthcare providers are increasing investment in portable biomarker testing platforms because immediate diagnostic information accelerates clinical decision-making and reduces delays in treatment initiation. Manufacturers are improving analytical performance, connectivity, and workflow integration to strengthen adoption across diverse healthcare environments. Continued expansion of decentralized diagnostics supports long-term growth of cardiovascular biomarker panel utilization.

Market Restraints

• High costs associated with automated multiplex immunoassay platforms and advanced laboratory infrastructure limit adoption among smaller healthcare facilities. Variability in reimbursement policies for multiplex cardiovascular biomarker testing restricts broader implementation despite expanding clinical evidence. Standardization challenges across assay platforms and biomarker interpretation protocols create variability in clinical adoption and laboratory workflow. Additionally, the complexity of integrating advanced biomarker panels into routine clinical practice can present operational hurdles for some laboratories.

Technology and Segment Insights

By Biomarker Type

• Cardiac troponin panels represent the largest segment because high-sensitivity troponin assays remain the clinical standard for diagnosing myocardial injury and acute myocardial infarction. Hospitals and emergency departments continue expanding adoption because earlier detection enables rapid treatment initiation and improves patient outcomes. Natriuretic peptide (BNP/NT-proBNP) panels are essential for diagnosing and managing heart failure, providing critical information for treatment decisions. CK-MB panels and myoglobin panels continue supporting diagnosis of acute myocardial infarction, though their use is increasingly complemented by more specific troponin assays. Inflammatory biomarker panels (hs-CRP, IL-6) are gaining importance for cardiovascular risk assessment and monitoring inflammatory processes. Multi-marker cardiovascular risk panels are emerging as comprehensive tools for evaluating overall cardiovascular risk and guiding preventive strategies.

By Technology

• Immunoassays remain the dominant technology because they provide highly sensitive and specific detection of cardiac biomarkers across centralized laboratory environments. Hospitals and diagnostic laboratories continue relying on automated immunoassay analyzers to support high testing volumes while maintaining analytical consistency. Chemiluminescence immunoassays (CLIA) offer enhanced sensitivity and broader dynamic ranges, supporting detection of biomarkers at very low concentrations. Enzyme-linked immunosorbent assays (ELISA) remain important for research and lower-volume testing applications. Multiplex assays are gaining adoption because they enable simultaneous measurement of multiple biomarkers, improving laboratory efficiency and providing more comprehensive clinical information. Point-of-care testing platforms are expanding because rapid turnaround times support immediate clinical decision-making in emergency and outpatient settings.

By End User

• Hospitals account for the largest share of cardiovascular biomarker panel utilization because emergency departments, intensive care units, and cardiology departments require rapid biochemical assessment for acute cardiovascular conditions. Diagnostic laboratories are expanding automated testing capabilities to accommodate growing volumes and support comprehensive biomarker panels. Cardiology clinics are adopting point-of-care and laboratory-based testing to support outpatient management. Academic and research institutes contribute to biomarker discovery and clinical validation. Ambulatory care centers are increasingly utilizing point-of-care testing for rapid assessment in decentralized settings.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies with strong immunodiagnostics portfolios. F. Hoffmann-La Roche Ltd. differentiates itself through one of the industry's most comprehensive cardiovascular immunodiagnostics portfolios, including its Elecsys high-sensitivity cardiac troponin T and NT-proBNP assays, supported by highly automated laboratory platforms. Abbott Laboratories maintains a leading position by combining high-sensitivity cardiovascular biomarkers with scalable automated immunoassay platforms, including the ARCHITECT and Alinity systems. Siemens Healthineers AG distinguishes itself through its ability to integrate laboratory diagnostics, imaging, and digital health into comprehensive cardiovascular care solutions, with its Atellica Solution supporting automated high-volume biomarker testing. Beckman Coulter, Inc. (Danaher Corporation) focuses on high-performance immunoassays and laboratory automation, including its Access high-sensitivity Troponin I assay. Thermo Fisher Scientific Inc. provides broad life sciences and clinical diagnostics expertise supporting both routine testing and advanced biomarker research. bioMerieux SA maintains a strong position through its expertise in clinical diagnostics and immunoassays. Sysmex Corporation continues expanding its immunochemistry portfolio. QuidelOrtho Corporation combines laboratory-based and point-of-care immunodiagnostic solutions.
• Strategic developments include increasing integration of artificial intelligence with laboratory diagnostics, expansion of multiplex assay capabilities, and development of point-of-care testing platforms. Companies are forming collaborations with healthcare providers and research institutions to validate novel biomarkers and improve clinical adoption. Product launches are focused on high-sensitivity assays, automated laboratory systems, and digital connectivity solutions. Companies that successfully combine high-quality assays, laboratory automation, and digital health solutions are expected to strengthen their competitive positions.

Conclusion

• The cardiovascular biomarker panels market is poised for significant growth, driven by the rising prevalence of cardiovascular diseases and the shift toward comprehensive, multiplex diagnostic strategies. The evolution from single-analyte testing toward integrated multimarker panels supported by automation and digital health is reshaping clinical practice. Companies that successfully develop highly standardized, clinically validated, and digitally integrated biomarker panel solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding cardiovascular screening across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Cardiovascular Biomarker Panels Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2031)
• 3.7 Classification of Cardiovascular Biomarkers
• 3.8 Disease Burden & Unmet Clinical Needs
• 3.9 Cardiovascular Disease Epidemiology & Prevalence Analysis
• 3.10 Biomarker Testing Volume Analysis
• 3.11 Clinical Adoption Pathway for Multiplex Biomarker Panels
• 3.12 Role of Biomarker Panels in Precision Cardiovascular Medicine

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Discovery
• 6.2 Multiplex Assay Development
• 6.3 AI-Enabled Biomarker Interpretation
• 6.4 High-Sensitivity Cardiac Biomarker Innovations
• 6.5 Precision Medicine & Companion Diagnostics
• 6.6 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways for IVD Biomarker Panels
• 7.3 Quality & Compliance Requirements

8. Cardiovascular Biomarker Panels Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology
• 8.3 Analysis by Clinical Application
• 8.4 Analysis by End User

9. Cardiovascular Biomarker Panels Market Segment Analysis (2021-2031)

• 9.1 By Biomarker Type
  • 9.1.1 Cardiac Troponin Panels
  • 9.1.2 Natriuretic Peptide (BNP/NT-proBNP) Panels
  • 9.1.3 CK-MB Panels
  • 9.1.4 Myoglobin Panels
  • 9.1.5 Inflammatory Biomarker Panels (hs-CRP, IL-6)
  • 9.1.6 Multi-marker Cardiovascular Risk Panels
• 9.2 By Technology
  • 9.2.1 Immunoassays
  • 9.2.2 Chemiluminescence Immunoassays (CLIA)
  • 9.2.3 Enzyme-Linked Immunosorbent Assays (ELISA)
  • 9.2.4 Multiplex Assays
  • 9.2.5 Point-of-Care Testing Platforms
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Cardiology Clinics
  • 9.3.4 Academic & Research Institutes
  • 9.3.5 Ambulatory Care Centers

10. Cardiovascular Biomarker Panels Market Geographical Analysis (2021-2031)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Cardiovascular Biomarker Panels Market Country Analysis (2021-2031)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers, Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches & Regulatory Approvals

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Abbott Laboratories
• 13.3 Siemens Healthineers AG
• 13.4 Beckman Coulter, Inc. (Danaher Corporation)
• 13.5 bioMerieux SA
• 13.6 QuidelOrtho Corporation
• 13.7 Thermo Fisher Scientific Inc.
• 13.8 Sysmex Corporation
• 13.9 Becton, Dickinson and Company (BD)
• 13.10 Randox Laboratories Ltd.
• 13.11 Fujirebio Holdings, Inc.
• 13.12 Ortho Clinical Diagnostics
• 13.13 Bio-Rad Laboratories, Inc.
• 13.14 DiaSorin S.p.A.
• 13.15 SEKISUI Diagnostics

14. Cardiovascular Biomarker Panels Market Commercial Forecast Analysis

• 14.1 Cardiac Troponin Panels
• 14.2 Natriuretic Peptide (BNP/NT-proBNP) Panels
• 14.3 Inflammatory Biomarker Panels
• 14.4 Multi-marker Cardiovascular Risk Panels
• 14.5 Point-of-Care Biomarker Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital & Private Equity Trends
• 15.2 Government & Public Health Funding
• 15.3 Research & Development Investments

16. Future Outlook

• 16.1 Emerging Growth Opportunities
• 16.2 Future Industry Trends
• 16.3 Strategic Recommendations